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Objectives. Assessment of left ventricular (LV) systolic function in patients with atrial ﬁbrillation can be diﬃcult. Acoustic
cardiography provides several parameters for quantifying LV systolic function. We evaluated the ability of acoustic cardiography
to detect LV systolic dysfunction in patients with and without atrial ﬁbrillation. Design. We studied 194 patients who underwent
acoustic cardiography and cardiac catheterization including measurement of angiographic ejection fraction (EF) and maximum
LVdP/dt.LVsystolicdysfunctionwasdeﬁnedasLVmaximumdP/dt< 1600mmHg/s.Acousticcardiographicparametersincluded
electromechanical activation time (EMAT) and the systolic dysfunction index (SDI). Results. Acoustic cardiography detected
systolic dysfunction with high speciﬁcity and moderate sensitivity with similar performance to EF (sensitivity/speciﬁcity without
aﬁb: EMAT 30/96, SDI 40/90, EF at 35% 30/96; sensitivity/speciﬁcity with aﬁb: EMAT 64/82, SDI 59/100, EF at 35% 45/82).
Conclusions. Acoustic cardiography can be used for diagnosis of LV systolic dysfunction in atrial ﬁbrillation.
1.Introduction
Atrial ﬁbrillation is a highly prevalent arrhythmia, par-
ticularly in patients with heart failure. Atrial ﬁbrillation
signiﬁcantly increases with age in patients with heart failure,
and the prevalence increases from <10% in those with New
York Heart Association (NYHA) functional class I to almost
50% in those patients with NYHA class IV [1, 2]. It is
estimated that two-thirds of patients with heart failure are
over 65 years old and 4.5 times more likely to have atrial
ﬁ b r i l l a t i o ni nm e na n d5 . 9t i m e sm o r el i k e l yi nw o m e n[ 3].
Assessing systolic function in atrial ﬁbrillation is especially
important since both pharmacological and device-based
therapiesexist.However,duetothebeat-to-beatvariationsin
preload with atrial ﬁbrillation, assessment of left ventricular
systolic function is diﬃcult. Systolic function is most com-
monly assessed using the ejection fraction (EF) measured by
angiographic, echocardiographic, or radionuclide methods
with varying success as schemas continue to be developed to
improveaccuracyduringatrialﬁbrillation[4–6].Inaddition,
invasive or imaging technologies such as cardiac magnetic
resonance to quantify systolic function are expensive and not
always readily available.
Acoustic cardiography (Audicor, Inovise Medical, Inc.,
Beaverton,OR)recordsandalgorithmicallyinterpretssimul-
taneous digital ECG and acoustic data by using the same
array of electrodes used for a standard ECG. However, in the
V3 and V4 positions, it employs dual sensors that acquire
both ECG and sound data. Measuring systolic time intervals
and diastolic heart sounds, acoustic cardiography allows
reliable assessment of hemodynamics [7–10]. Parameters
produced by this technique include those to assess systolic
function [11] including EMAT (electrical mechanical acti-
vation time, Q wave onset to the S1 interval), the presence
of a third heart sound (S3), and SDI (systolic dysfunction
index, a combination of EMAT, S3, QRS duration and QR
interval). This diagnostic method is particularly appropriate
in environments, where echocardiography or invasive assess-
ment of LV function is not available [12] or when serial
measurements are desired.2 Cardiology Research and Practice
The goal of the present paper was to evaluate the use
of acoustic cardiography as a rapid, noninvasive method to
assess LV systolic dysfunction (LVSD) in a population with
atrial ﬁbrillation that also underwent invasive diagnostic
evaluation. We tested the hypothesis that acoustic cardio-
graphy could discriminate those patients with and without
LV dysfunction independent of whether or not they also had
atrial ﬁbrillation.
2.MaterialsandMethods
2.1. Subjects. The local Medical Ethics Committee approved
the study. After obtaining written informed consent from
each patient, we evaluated a convenience sample of 194
patients who underwent diagnostic cardiac catheterization.
Patients were without food for at least 6 hours. Short-
acting diuretics were withheld on the morning of the
catheterization but other cardiac drugs were administered as
usual.
All the subjects had measurement of left-ventricular
EF and LV end-diastolic pressure (LVEDP). Left-ventricular
maximum dP/dt (i.e., LV max(dP/dt)) was measured using a
manometer-tipped catheter (Volcano Inc., Parker, TX, USA)
in 108 patients and a ﬂuid-ﬁlled catheter in the remaining
86. LV max(dP/dt) was calculated automatically (Schwarzer
GmbH Medical Equipment, Munich, Germany) in normally
conducted beats. Only recordings with a minimum of at
least 4 normally conducted beats were used including in
patients with atrial ﬁbrillation. Values of LV max(dP/dt) of
<1600mmHg/swereconsideredtobeamarkerofLVSD[13–
15]. Left ventricular ejection fraction was calculated using
monoplane ventriculography. Measurements of right atrial,
right ventricular and pulmonary artery systolic and wedge
pressures were performed with multipurpose catheters.
2.2. Acoustic Cardiography. Acoustic cardiography data were
recorded immediately prior to cardiac catheterization with
the patient in a supine position. This quantitative method
provides parameters for assessing both systolic and diastolic
LV function. In the present study, we evaluated two systolic
parameters—the electromechanical activation time (EMAT)
and the systolic dysfunction index (SDI). EMAT measures
the time interval from the onset of the QRS complex to
the point of maximum intensity of the ﬁrst heart sound.
Therefore, EMAT indicates the amount of time required for
the LV to generate suﬃcient force to close the mitral valve
and reﬂects the velocity of force generated during systole.
TheSDIcombinesEMAT,QRSduration,QRintervalandthe
strength of the third heart sound into one parameter (SDI =
transform (QRS duration ∗ QR interval ∗ S3 strength ∗
EMAT/RR interval)). The SDI value undergoes a nonlinear
transformation and is then reported as a value between 0
and 10, where SDI > 5 indicates systolic dysfunction deﬁned
as EF < 50%, and SDI > 7.5 indicates EF < 35% and
elevated ﬁlling pressure. The SDI was developed on separate
learn and test sets of invasive cardiac catheterization data
that provided both EF and LV end-diastolic pressure. The
acoustic cardiographic parameters are calculated from a 10-
second recording of data that typically involves averaging
of measurements from 8 to 12 beats. We hypothesized that
EMAT and SDI could be used to detect LVSD.
2.3. Statistical Analysis. Data are presented as mean values
and standard deviations with minimum and maximum
values as ranges for continuous variables. Categoric data are
presented as exact numbers and proportions. We tested the
null hypothesis for continuous data using the unpaired T-
test for patients with and without atrial ﬁbrillation and a
priori chose alpha <0.05 to indicate statistical signiﬁcance.
We also generated ROC curves to determine the diagnostic
sensitivities and speciﬁcities for LVSD and to calculate
positive and negative likelihood ratios. Unlike positive and
negative predictive values, positive and negative likelihood
ratios are independent of the prevalence of the abnormality
inthepopulationbeingtested[16].Toavoiddividingbyzero,
we set the positive likelihood ratio equal to sensitivity in the
cases in which speciﬁcity was 100%.
3. Results
There were a total of 194 subjects recruited for this study.
The mean age of the 155 subjects without atrial ﬁbrillation
was 62.6 ± 11.8 years (range: 22 to 86 years), and 102 (66%)
of the subjects were men, whereas the mean age of the 39
patients with atrial ﬁbrillation was 67.3 ± 10.7y e a r s( r a n g e :
43 to 85 years) and 32 (82%) were men.
One hundred three (66%) of the subjects without atrial
ﬁbrillation had LVSD (a LV max(dP/dt) < 1600mmHg/s),
while 22 (56%) of the subjects with atrial ﬁbrillation had
LVSD. In the population without atrial ﬁbrillation, the
LV max(dP/dt) was 1474 ± 479mmHg/s (range: 480 to
2928mmHg/s) and 1589 ± 534mmHg/s (range: 648 to
2832mmHg/s) in the group with atrial ﬁbrillation. Table 1
shows that the subjects with LVSD had signiﬁcantly lower
mean values of EF, larger end-diastolic and end-systolic
volumes, and greater mean values of EMAT and the systolic
dysfunction index. Heart rate was signiﬁcantly higher and
EMAT longer in the populations with atrial ﬁbrillation
independent of whether there was LVSD or not.
Figure 1 shows the means and 95% conﬁdence intervals
of EMAT, the systolic dysfunction index and EF. In both the
patients with and without atrial ﬁbrillation, EMAT and the
systolic dysfunction index discriminate between the presence
versus the absence of LVSD, as does the ejection fraction.
Figure 1 also reveals that EMAT is higher in patients with
atrial ﬁbrillation compared to those in sinus rhythm both
with and without LVSD suggesting that atrial ﬁbrillation
alone impairs LV contractility. The ROC curves in Figure 2
reveal that EMAT and SDI are similar in performance for the
groups with and without atrial ﬁbrillation.
Table 2 showssensitivities,speciﬁcitiesandthelikelihood
ratios for EMAT, SDI, and EF at common thresholds to
detect LV systolic dysfunction in groups with and without
atrial ﬁbrillation. Note the similar performances for EMAT
and SDI independent of the presence of atrial ﬁbrillation.
Speciﬁcities were high for all populations for EMAT and
SDI, with moderate sensitivities (ranging from 30 to 64).Cardiology Research and Practice 3
Table 1: Demographic and clinical characteristics.
Parameter No Aﬁb, No LVSD (N = 52) No Aﬁb, LVSD (N = 103) Aﬁb, No LVSD (N = 17) Aﬁb, LVSD (N = 22)
Age (years) 63.8 ±11.6,27 −81 62.0 ±12.0,22 −86 66.7 ±11.2,43 −85 67.7 ±10.4,43 −85
∗
Male (%) 63% 67% 82% 82%
Height (cm) 170 ±10,141 −190 169 ± 9.1,149 −196 173 ±11,152 −192 172 ±10.6,150 −190
Weight (kg) 80.1 ±19.4,52 −148 78.9 ±15.0,51 −117 91.4 ±24.4,49 −160 86.5 ±22.0,53 −132
Heart rate (bpm) 75.3 ±16.0,42 −129 74.5 ±14.9,43 −142 99.0 ±28.6,56 −149
∗ 90.7 ±14.8,68 −119
∗
QRS duration (ms) 96.4 ±16.1,59 −143 121 ±36.1,68 −235
∧ 90.2 ±9.8,74 −102 110 ±26.1,81 −171
∧
QTc interval (ms) 418 ±28.7,319 −465 430 ±32.8,372 −528
∧ 407 ±29.1,374 −466 404 ±33.4,321 −483
∗
EMAT (ms) 83.7 ±16.5,58 −164 100 ±19.7,60 −164
∧ 101 ±16.8,79 −147
∗ 116 ±20.5,88 −164
∧∗
SDI 3.2 ±1.6,0.8 −7.44 .9 ±2.6,0.7 −10
∧ 3.8 ±0.7,2.7 −4.66 .0 ±2.1,2.9 −10
∧
LV EDP (mmHg) 19.9 ±6.5,4 −37 18.6 ±7.6,4 −39 16.4 ±7.4,5 −27 15.1 ±6.6,8 −37
∗
LV max (dP/dt) (mmHg/s) 2039 ±301,1608 −2928 1189 ±238,480 −1584
∧ 2090 ±342,1632 −2832 1201 ±254,648 −1584
∧
LV ejection fraction (%) 62.3 ±14.0,19 −83 43.4 ±18.3,8 −84
∧ 57.1 ±21.1,10 −86 40.7 ±19.2,15 −81
∧
EDV (ml) 116 ±35.3,51 −206 155 ±63.4,47 −337
∧ 107 ±32.5,50 −146 144 ±59.7,25 −264
∧
ESV (ml) 51.1 ±24.3,18 −135 96.0 ±56.8,19 −261
∧ 49.9 ±29.5,19 −113 97.5 ±59.7,40 −186
∧
Aﬁb: atrial ﬁbrillation; LV EDP: left ventricular end-diastolic pressure; EDV: end-diastolic volume; EMAT: electromechanical activation time; ESV: end-
systolic volume; LVSD: left ventricular systolic dysfunction, deﬁned as LV max(dP/dt) < 1600mmHg/s; SDI: systolic dysfunction index.























95% conﬁdence intervals for EMAT 95% conﬁdence intervals for SDI 95% conﬁdence intervals for EF (%)
No Aﬁb Aﬁb No Aﬁb Aﬁb No Aﬁb Aﬁb
Figure 1: The means and 95% conﬁdence intervals for electromechanical activation time (EMAT), the systolic dysfunction index (SDI)
and ejection fraction (EF) for populations with and without left ventricular systolic dysfunction (LVSD). Aﬁb: atrial ﬁbrillation; EMAT:
electromechanicalactivationtime,msec;SDI:systolicdysfunctionindex;EF:ejectionfraction,%;LVSD:leftventricularsystolicdysfunction,
deﬁned as LV max(dP/dt) < 1600mmHg/s.
Ejection fraction had reduced speciﬁcities at similar sensitiv-
ities to the acoustic cardiographic parameters.
4. Discussion
Noninvasive methods are often employed to identify patients
with LVSD. Echocardiography measures several systolic
parameters but the beat-to-beat variations in preload with
atrial ﬁbrillation make accuracy diﬃcult. A study by Gos-
selink [17] found that varying left ventricular performance
during atrial ﬁbrillation is determined by cycle length-
dependent contractile mechanisms including postextrasys-
tolic potentiation and mechanical restitution, but that beat-
to-beat changes in preload consistent with the Starling
mechanism are diminished after long and short preceding
intervals. Another study using simultaneous biplane views
of the left ventricle concludes that systolic function can be
accurately assessed in atrial ﬁbrillation by averaging 2 beats
withequalsubsequentcyclelengthsgreaterthan500ms[18].
Dubrey [19] found that in atrial ﬁbrillation the average4 Cardiology Research and Practice
Table 2: Performances of EMAT, SDI, and EF to detect LVSD.
Parameter Group % Sensitivity % Speciﬁcity Pos LR Neg LR
EMAT@110 No AFib 30 96 7.8 1.4
Aﬁb 64 82 3.6 2.3
SDI@5.0 No Aﬁb 40 90 4.0 1.5
Aﬁb 59 100 59 2.4
EF@35% No Aﬁb 30 96 7.8 1.4
Aﬁb 45 82 2.6 1.5
EF@50% No Aﬁb 69 81 3.6 2.6
Aﬁb 64 76 2.7 2.1
EMAT: electromechanical activation time, msec; SDI: systolic dysfunction index; EF: ejection fraction, %; LVSD: left ventricular systolic dysfunction, deﬁned
as LV max(dP/dt) < 1600mmHg/s, Aﬁb: atrial ﬁbrillation, Pos LR: positive likelihood ratio, Neg LR: negative likelihood ratio.
number of beats required to determine cardiac output
using Doppler measurements was approximately 13 beats
(ranging 4 to 17 beats) or three times that required in sinus
rhythm. Therefore, the time required and skill necessary to
perform echocardiographic examinations in patients with
atrial ﬁbrillation are quite high.
Cardiac magnetic resonance imaging (CMRI) has supe-
riorinterobserverandintraobservervariabilitythanechocar-
diography and is the preferred technique by some clini-
cians for volume and ejection fraction estimation in heart
failure patients due to its three-dimensional technique for
nonsymmetric ventricles and excellent image quality [20].
But recent literature is mixed on its routine use in the
management of atrial ﬁbrillation for evaluation of systolic
function. In a recent review of cardiovascular imaging in
atrial ﬁbrillation, Wazni et al. recommend the use of CMRI
for precise visualization of left atrial and pulmonary vein
anatomy [21] but recommend echocardiography for clinical
management.
The acoustic cardiography method is a rapid and inex-
pensive test and does not have the above limitations inherent
inechocardiographyorcardiacmagnetic resonanceimaging.
The procedure needed to obtain EMAT and SDI requires
no more time, eﬀort, or technical skill than that needed for
recording a standard 12-lead ECG, and the analysis of the
dataisfullyautomated[22].Theparametersarereproducible
and represent an average over the 10-second recording. This
averaging of values over multiple cardiac cycles improves
their performance by minimizing the eﬀect of varying
preceding RR intervals as demonstrated for systolic time
intervals over 30 years ago [23, 24].
In the present paper, we deﬁned left ventricular systolic
d y s f u n c t i o na sL Vm a x ( d P / d t )<1600, a threshold value
similar to that used by other investigators [13–15]. Left-
ventricular maximum dP/dt is sensitive to changes in
contractility and is aﬀected to a lesser extent by both preload
and afterload [25, 26]. Left ventricular max(dP/dt) may be
delayed and may follow the opening of the aortic valve in
patients with severe LVSD or with marked vasodilatation
with very low aortic diastolic pressures. Its sensitivity to
preload is greater in ventricles with enhanced contractility,
but is reduced in LVSD [27]. Nevertheless, reduced LV
max(dP/dt) is clinically important because of its association
with a poor prognosis [28–30].
EMAT also reﬂects the rate of left ventricular pressure
development since it measures the time required to close
the mitral valve. EMAT is similar to LV max(dP/dt) in
that it is inﬂuenced by preload via the Starling mechanism
invoked by left-ventricular ﬁlling pressure. However, EMAT
is not aﬀected by afterload resulting from changing systemic
vascularresistance or aortic valvular obstruction. In this way,
EMAT can be a robust measurement in atrial ﬁbrillation
even with other concurrent disease conditions. The systolic
dysfunction index combines EMAT with QRS duration, the
QR interval, and the strength of the third heart sound. It was
developed to provide good detection of systolic dysfunction
atvaluesabove5.0,andabove7.5detectssystolicdysfunction
with elevated ﬁlling pressures [31]. As a continuous variable
SDIcanprovideameanstotrackchangesinsystolicfunction
and ﬁlling pressures.
Diminished LV max(dP/dt) is a well-established and
accurate marker of LV systolic dysfunction. The present
study has shown that acoustic cardiographic parameters
discriminate well between normal versus low values of LV
max(dP/dt) in patients with atrial ﬁbrillation. However, it
would be useful to know if these parameters also identify
patients who are at increased risk of adverse clinical out-
comes. Nonacute heart failure patients (n = 128) were stud-
ied using acoustic cardiography and echocardiography (per-
sonal communication, M. Zuber). They were followed for
27.1 ± 14.8 months and all heart failure events and all-cause
deaths were recorded (24 events total). Echocardiographic
andacousticcardiographicmeasurementswereevaluatedfor
sensitivity at 90% speciﬁcity and the corresponding odds
ratios. Echocardiographic parameters had lower sensitivity
(T deceleration time 26% at 180ms; EF 17% at 45%; E/E
 
ratio 18% at 15; E/A 25% at 1.8) than the acoustic cardio-
graphic parameters (EMAT 38% at 120ms; SDI 45% at 5.0).
The echocardiographic measurements also had lower odds
ratios (ranging from 0.4 for T deceleration time to 2.2 for
E/E
  ratio) than acoustic cardiographic parameters (ranging
from5.9forEMATto7.5forSDI).This study wouldindicate
thatbothEMA TandSDIha v esuperiorpr ognosticvalueo v er
the traditional echocardiographic measurements.Cardiology Research and Practice 5




















































































Figure 2: Receiver-operating characteristic (ROC) curves are presented for electromechanical activation time, the systolic dysfunction index
and ejection fraction for populations with (red curve) and without atrial ﬁbrillation (blue curve). Aﬁb: atrial ﬁbrillation.
In another study of patients hospitalized for acute heart
failure (n = 45), acoustic cardiographic recordings were
taken within 24 hours of admission, before discharge and
2 weeks after discharge [32]. Adverse post-discharge events
were cardiac death or rehospitalization for heart failure.
Patients were followed for 242 ± 156 days. Predischarge and
2-week postdischarge %EMAT (deﬁned as EMAT divided by
the R-R interval) was signiﬁcantly associated with adverse
post-discharge events, with or without adjustment for age,
gender, left ventricular EF, E/E
  by Doppler echocardiogra-
phy, and serum N-terminal probrain natriuretic peptide.
We conclude that acoustic cardiography detects left ven-
tricular systolic dysfunction in patients with atrial ﬁbrilla-
tion.Thisisparticularlyimportantwhenrepeatassessmentis
desired and in situations where invasive (cardiac catheteriza-
tion) or noninvasive (echocardiographic or cardiac magnetic
resonance imaging) assessment of LV function is not feasible
or readily available.
5. Limitationsof the Study
Although it is similar to older methods used to obtain
systolic time intervals, acoustic cardiography is a relatively
new method of quantifying cardiac function and has limited
routine use. There was not a control group of healthy
subjects due to the fact that this was an invasive car-
diac catheterization study. Not all the recordings of left
ventricular dP/dt were performed with manometer-tipped
catheters. Left ventricular ejection fraction was calculated
using monoplane ventriculography. Although short-acting
diuretics were withheld on the morning of the catheteri-
zation, the subjects varied with respect to the types and6 Cardiology Research and Practice
dosages of other cardiac drugs that they were receiving. Since
beta adrenergic blockers, vasodilators, ACE inhibitors and
other cardiac drugs inﬂuence ventricular performance, this
pharmacological variability may have aﬀected our results.
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